دورية أكاديمية
Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy.
| العنوان: | Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy. |
|---|---|
| المؤلفون: | Koemans WJ; Department of Surgical Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., van der Kaaij RT; Department of Surgical Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Wassenaar ECE; Departments of Surgery, Sint Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, the Netherlands., Grootscholten C; Department of Gastrointestinal Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Boot H; Department of Gastrointestinal Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Boerma D; Departments of Surgery, Sint Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, the Netherlands., Los M; Department of Medical Oncology, Sint Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, the Netherlands., Imhof O; Clinical Perfusion, Heartbeat. Kerkstraat 3a, 3755 CK, Eemnes, the Netherlands., Schellens JHM; Department of Clinical Pharmacology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Rosing H; Department of Pharmacy, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Huitema ADR; Department of Pharmacy, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht. Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands., van Sandick JW; Department of Surgical Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: j.v.sandick@nki.nl. |
| المصدر: | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 Feb; Vol. 47 (2), pp. 486-489. Date of Electronic Publication: 2020 Aug 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 8504356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2157 (Electronic) Linking ISSN: 07487983 NLM ISO Abbreviation: Eur J Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: London ; New York : Academic Press, [1985- |
| مواضيع طبية MeSH: | Docetaxel/*administration & dosage , Oxaliplatin/*administration & dosage , Peritoneal Neoplasms/*therapy , Peritonitis/*therapy , Stomach Neoplasms/*therapy, Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Combined Modality Therapy ; Docetaxel/pharmacokinetics ; Dose-Response Relationship, Drug ; Gastrectomy ; Humans ; Injections, Intraperitoneal ; Oxaliplatin/pharmacokinetics ; Peritoneal Neoplasms/complications ; Peritoneal Neoplasms/metabolism ; Peritonitis/etiology ; Stomach Neoplasms/complications ; Stomach Neoplasms/metabolism |
| مستخلص: | In the PERISCOPE I study, gastric cancer patients with limited peritoneal dissemination were treated with systemic chemotherapy followed by (sub)total gastrectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with 460 mg/m 2 hyperthermic oxaliplatin followed by normothermic docetaxel in escalating doses (0, 50, 75 mg/m 2 ). In total, 25 patients completed the study protocol. Plasma samples were collected before the start of the HIPEC procedure, after oxaliplatin washing, after docetaxel washing and the following morning. Median peak plasma concentrations were 5.5∗10 -3 mg/ml for oxaliplatin, 89∗10 -6 mg/ml for docetaxel (dose 50 mg/m 2 ) and 113∗10 -6 mg/ml for docetacel (dose 75 mg/m2). The following morning median plasma concentrations were 32% and 4% of the measured peak concentrations for oxaliplatin and docetaxel, respectively. For both cytostatic agents, no correlation was found between intraperitoneal fluid concentration and peak plasma concentration. High doses oxaliplatin and docetaxel can be given intraperitoneally without causing potentially toxic systemic concentrations. Competing Interests: Declaration of competing interest None. (Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.) |
| التعليقات: | Comment in: Eur J Surg Oncol. 2020 Dec;46(12):2343. (PMID: 32981795) Comment in: Eur J Surg Oncol. 2020 Sep 19;:null. (PMID: 32988701) |
| فهرسة مساهمة: | Keywords: Docetaxel; Gastric cancer; Hyperthermic intraperitoneal chemotherapy; Oxaliplatin; Perfusion; Plasma concentration |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 04ZR38536J (Oxaliplatin) 15H5577CQD (Docetaxel) |
| تواريخ الأحداث: | Date Created: 20200818 Date Completed: 20210422 Latest Revision: 20210927 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.ejso.2020.07.037 |
| PMID: | 32800401 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-2157 |
|---|---|
| DOI: | 10.1016/j.ejso.2020.07.037 |